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5.6) post-DCBT. Of 103 progression-free survivors at 1-year,
26 (25%) were on high, 26 (25%) on intermediate, 18 (17%) on
low dose sys.IS, & 33 (32%) were on no sys.IS. The number of
patients on any sys.IS decreased to 30% in evaluable pro-
gression-free survivors at 2-years, & 18% at 3-years. A total of
84/129 (65%) patients survive progression-free to date from
the day 100 landmark with 24 having died of TRM (17 GVHD-
related), 1 from relapsed sarcoma, & 20 have relapsed/pro-
gressed. The 3-year incidence of TRM according tomaximum
day 100 aGVHD grade was 11% (95%CI: 4-22) in grade 0-I &
24% (95%CI: 15-34) in grade II-IV patients, p ¼ 0.14. The 3-
year incidence of relapse was 20% (95%CI: 10-34) in grade 0-I
& 11% (95%CI: 6-20) in grade II-IV patients, p ¼ 0.54. Overall,
there was no difference in the 3-year PFS of 69% (95%CI: 56-
84) in those whose day 100 aGVHD grade was 0-I when
compared to the 65% (95%CI: 55-76) PFS in patients whose
aGVHD grade was II-IV (Figure).
Conclusions: In patients alive at day 100, most will achieve
sustained cessation of sys.IS despite initial aGVHD.Moreover,
while the contribution of aGVHD to TRM is signiﬁcant, there
was no statistical difference in overall TRM in the GVHD
groups. Finally, grade 0-I versus II-IV aGVHD had no impact
on long-term PFS. Thus, despite an approximate 50% inci-
dence of grade II-IV aGVHD in DCBT recipients at our center
(Ponce et al, BBMT 2013), long-term PFS is not impacted in
day 100 survivors & the majority of patients are off IS after 2
years post-allograft.Figure 1. FEV1 and prednisone dose for Subject 8A and 14A505
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Sciences, National Institutes of Health, Bethesda, MDBronchiolitis Obliterans Syndrome (BOS) is a late pulmonary
complication of both lung and HSCT resulting in obstructive
lung disease. For the latter, BOS is thought to be a manifes-
tation of chronic graft versus host disease (cGVHD). The
mainstay of therapy is systemic immunosuppression, which
increases the risk of infection and reduces graft versus tumor
effects. We investigated whether targeted, local delivery of
inhaled cyclosporine could improve or stabilize lung func-
tion in BOS patients.
HSCT and lung transplant recipients with BOS were
eligible if they met the following inclusion criteria:
FEV1<75% predicted, FEV1 decline >10% compared to pre-
transplant FEV1, no evidence of pulmonary infection as
causative etiology, and one of the following: FEV1/FVC ratio
<70%, air-trapping seen on CT scan or RV 120%, or evidence
of cGVHD affecting at least one other organ system. Subjects
received cyclosporine inhalation solution (CIS) 150 mg via
nebulizer 3 times weekly for 6 weeks before dose escalation
to 300mg three times weekly. Pharmacokinetic and lung
deposition studies were performed. The primary endpoint
was change in FEV1 at study completion (average of week 18
and 19) compared to study baseline.
16 subjects have been enrolled (median age: 45 years;
range: 14-73); 14 had HSCT-associated BOS, and 2 had lung-
transplant-associated BOS. The median time from BOS diag-
nosis to study enrollment was 9 months (range: 2-37). The
median FEV1 at study entry was 1.1 liters (range: 0.5-2.11).
One patient suffered a severe adverse event with CIS (cough,
bronchospasm, and dyspnea requiring hospitalization).
Adverse events associated with CIS occurred in 11/12 patients
and included grade 2 (range 1-3) cough, bronchospasm, and
dyspnea that occurred primarily during inhalation.
Of the 12 evaluable subjects, 4 subjects went off-study (pa-
tient choice) prior to completion of the 18 weeks, and were
considered non-responders. Responses were observed in 5/10
subjects (50%) with BOS following HSCT. Among responding
patients who had an improvement in their FEV1, 3 were also
able to decrease their systemic steroid dose (Figure 1). The
median peak systemic absorption of cyclosporine was 99
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deposition studies showed the total deposited dose averaged
13% (range: 4-20%) of the inhaled dose. Of note, 5 subjects
who showed a clinical beneﬁt on study were subsequently
enrolled onto a CIS extension protocol.
Conclusion: These data are the ﬁrst to establish that CIS is
safe and can stabilize or improve lung function in HSCT re-
cipients with severe BOS, allowing systemic immunosup-
pression to be reduced. Importantly, lung deposition studies
revealed substantial delivery of CIS could be achieved in the
airways with only minimal systemic absorption.
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Blocking Notch signaling after allogeneic bone marrow
transplantation prevents acute graft-versus-host disease
(GVHD) in mice, with key roles for Notch1/2 receptors and
Delta-like-1/4 ligands (Dll1/4) (Zhang, Blood 2011; Tran, JCI
2013). To investigate the consequences of Notch inhibition in
alloantigen-speciﬁc T cells, we identiﬁed a short 2-day win-
dow of Notch activity early after transplantation during
which Notch blockade is critical for maximal prevention of
acute GVHD. We describe new mechanistic models to study
alloantigen-speciﬁc T-cells within this window, and provide
insights into early events associated with Notch blockade. In
a MHC-mismatched model, transgenic C57Bl/6 CD4+ 4C T-
cells directly recognizing host I-Ad alloantigens induced le-
thal GVHD in BALB/c recipients. 4C CD4+ T-cells were sensi-
tive to Notch blockade, which resulted in the downregulation
of Notch target genes in and impaired production of in-
ﬂammatory cytokines, concordant with ﬁndings in poly-
clonal responses (Zhang, Blood 2011; Tran, JCI 2013).
Nonetheless, serial analysis revealed preserved 4C CD4+ T-
cell activation, proliferation and expansion upon Dll1/4
blockade. In the B10.D2/BALB/c MHC-matched model of
sclerodermatous GVHD, donor-derived CD4+Vb3+ T-cells,
responding to a Mtv6-encoded BALB/c superantigen,
demonstrated massive expansion and dominant Th1 polari-
zation of Vb3+ T-cells in lymphoid tissues and the liver.
Despite this, Notch blockade in Vb3+ T-cells inhibited cyto-
kine production, but preserved activation and proliferation.
These ﬁndings document dissociated effects of Notch inhi-
bition on proliferation and cytokine production in alloan-
tigen-speciﬁc T-cells, allowing further focused evaluation of
Notch signaling functions in alloimmunity.
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Purpose: Haplo-identical transplants are increasingly used
in hematopoietic stem cell transplantation (HSCT). Do haplo-
identical transplants have a stronger graft-versus-leukemia
(GVL) effect?
Patients and Methods:We analyzed 10,679 patients with
acute leukemia undergoing HSCT from an HLA-matched
sibling donor (MSD, n¼9,815), or a haplo-identical donor
(2 HLA-antigen disparity, n¼864) between 2007e2012,
reported to the European Group for Blood and Marrow
Transplantation. In a Cox regression model, acute and
chronic GVHD were added as time-dependent variables.
Results: In the multivariate analysis, there was no differ-
ence in relapse probability between recipients of haplo-
identical or MSD grafts. This was seen in T-cell replete and
T-cell depleted grafts analyzed separately. Factors of
importance for relapse among T-cell replete grafts included
remission status at HSCT, Karnofsky score 80, acute GVHD
grade II, and chronic GVHD (p<10-5). Among patients
receiving T-cell depleted grafts, advanced disease (p<10-5)
and second remission (p¼0.01) compared to ﬁrst remission
were the strongest factors for leukemic relapse. Non-
relapse mortality was signiﬁcantly higher in the haplo
group versus MSD transplants among patients receiving T-
cell repleted grafts or T-cell depleted grafts (p<10-5).
Subsequently, leukemia-free survival was superior in the
MSD group of T-cell replete grafts (p<10-5) and T-cell
depleted grafts (p¼0.0006).
Conclusion: Risk of relapse was the same in patients with
acute leukemia in haplo-identical transplant recipients
compared with MSD transplants, suggesting a similar
GVL effect.508
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Introduction: We describe a case of a 52-year-old man with
history of refractory angioimmunoblastic T-cell lymphoma
11months aftermatched unrelated allogeneic hematopoietic
cell transplant with acute ﬁbrinous organizing pneumonitis
successfully treated with high dose steroids, tacrolimus, and
8 doses of etanercept.
Case presentation: A 52-year-old Caucasian male with a
history of refractory stage IV angioimmunoblastic T-cell
lymphoma treated with CHOP, ICE and Romidepsin fol-
lowed by ATG/TBI matched unrelated allogeneic he-
matopoietic cell transplant (HCT) in March 2013. He had
an uncomplicated course with the exception of mild
classic chronic GVHD of skin treated with topical ste-
roids. Eleven months after HCT, he was off
